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Abstract
Gliomas have been treated by a specialized team including neurosurgery, radia-
tion therapy, and neuro-oncology, as well as depending on integrated sophisticated 
facilities and multi-professional team. Despite these huge efforts to glioma treatment, 
glioblastoma, one of the most frequent gliomas, has median life expectance for just 
15 months, so these results are still an unmet need. Related to the systemic treatment, 
some cancer approaches have been revolutionized with new strategies, such as immu-
notherapy, although in neuro-oncology, this alternative still has challenges to over-
come. Throughout this chapter, relevant information and key points will be discussed 
to the best way to manage systemic treatment and improve glioma overall survival.
Keywords: gliomas, glioblastoma, astrocytoma, oligodendroglioma,  
immunotherapy, systemic treatment, chemotherapy
1. Introduction
Gliomas are the most common primary brain tumors [1]; their origin is from 
glial cells, i.e., from astrocytes, oligodendrocytes, and ependymal cells. Usually, it 
has diffused appearance, and depending on their molecular features, they may have 
different behaviors. The worst evolution is related to glioblastoma, in which the best 
treatment might provide the dismal evolution in 15 months of overall survival (OS) 
[2]. On the other hand, even with diffuse infiltration, when there are astrocytic 
features, the OS might be up to 7 years, and with oligodendroglial features [3, 4], 
the OS is around more than 10 years. So, these diseases are very heterogeneous in 
regard to pathogenesis, histopathology, and molecular and clinical features.
Related to glioma treatment, for the optimization of results [5], it is necessary 
to be aware of clinical variables, such as age, sex, Karnofsky Performance Status on 
admission, isocitrate dehydrogenase 1/2 mutation ratio, or resection rate. Besides, 
there is a necessity of engaged and specialized staff of neurosurgeons, radiation 
therapist, neuro-oncologist, anesthetist, radiologist, and a supportive staff, in an 
equipped and organized structure with facilities for brain tumor care.
The systemic approaches make part of glioma treatment, using drugs with direct 
action in tumor cells [6, 7], in association with radiation therapy [2] aiming to 
potentialize it, as an adjuvant therapy [8], and currently for action in the vascular 
formation [9, 10] and to modulate immune system.
2. Challenges for drug efficacy in CNS tumors
The preferred treatment for brain tumors has been attempting to maximize the 
degree of surgical resection. But irrespective of the relevance of this approach, it 
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has limitations with respect to gliomas due to the invasiveness of these tumors and 
their tendency to reside in or near important brain areas. Traditional postsurgi-
cal therapy for gliomas involved standard radiation therapy and chemotherapy. 
There are some issues which might be considered as a challenge to improve glioma 
treatment.
2.1 Blood-brain barrier (BBB), blood-cerebrospinal fluid barrier  
(blood-CSFB), and blood-tumor barrier
Anatomically, CNS can be subdivided into the parenchyma, meninges, special 
sense organs, cranial nerves, spinal nerves, and the ventricular system with its 
contents. All these structures are limited by boundaries under normal conditions, 
such as blood-brain barrier, blood-CSFB, and, in pathologic scenario, blood-tumor 
barrier. Under normal physiology, the BBB’s unique anatomic structure and the 
tightly regulated interplay of its cellular and acellular components allow for main-
tenance of brain homeostasis, regulation of influx and efflux, and protection from 
harm; these characteristics ensure an optimal environment for the neural network 
to function properly. It is not really a barrier but rather a communication “center,” 
responding to and passing signals between the CNS and blood [11]. It is constituted 
by cells that surround the vessels, the endothelium cells, which have been con-
sidered the central unit, and there is a growing understanding in the interactions 
of this central cell with other cells and systems, such as pericytes [12], astrocytes 
[13], and microglia. The integration among them results in maintenance of BBB 
permeability. There is a vast research to study the relation between this complex 
system and pathologies. Under pathologic conditions, these barriers might lose their 
permeability allowing easy traffic between the compartments.
Charge, lipophilicity, and molecular size are key issues for drugs to pass through 
BBB. Drugs currently in use for CNS tumors, for example, temozolomide and 
lomustine, can reach, despite BBB permeability, in areas with neoplastic enhance-
ment in imaging studies, which might have dysfunctional BBB and permit some 
drugs to get in easily.
For instance, BBB is part of complex environment that supports the balance and 
homeostasis of CNS, and it is as well a barrier both to drugs and chemotherapeutic 
agents and to immunotherapeutic agents.
2.2 Drug development
The best quality preclinical testing model would select appropriate molecular 
targets, determine the effectiveness of drugs directed against those targets and 
the ideal genetic and cellular context for their use, evaluate the toxicity of selected 
drugs, and identify relevant biomarkers demonstrating drug efficacy and specific-
ity to assist in subsequent clinical trials [14].
At the laboratory level, there are limitations of drug development for gliomas. 
Preclinical tests might be performed in in vitro tests or in animal model tests. In 
in vitro tests, there are limitations owing to cellular homogeneity that could not 
reproduce the real tumor environment and cellular heterogeneity; moreover, the 
systemic influences affect drug metabolism and distribution, and what’s more, in 
an animal model in which are based on xenografts inserts in flank or directly into 
the animal brain. But these models, despite working in preclinical models, usually 
fail to reproduce the same result at the clinical level. Another strategy that has been 
developed by using genetically engineered mouse models (GEMMs) [15] has shown 
that glial tumors spontaneously develop, mostly of high grade, after a variable 
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latent period. Such GEMMs are the best current models we have for approximating 
the biology of CNS neoplasms in humans.
Other efforts have been made in order to better understand the overlap of 
various models and human brain tumor behavior; in recent published paper 
[16], the authors have studied the differences and similarities in glioma biology 
as conveyed by transcriptomic patterns across four mammalian hosts: rats, mice, 
dogs, and humans. And they have found notable differences that were observed in 
gene expression patterns as well as related biological pathways and cell populations 
known to mediate key elements of glioma biology, including angiogenesis, immune 
evasion, and brain invasion.
2.3 Tumor heterogeneity
Tumor heterogeneity may keep tumor evolution and adaptation, which prevent 
personalized medicine agents to work [17]. It has been described in various tumor 
models, and this feature in gliomas allowed them to be resistant to several known 
drugs [18, 19].
There is a growing knowledge in the molecular and cellular basis of glioblas-
toma; Diane J. Aum [18], in her paper, introduced emerging concepts on the 
molecular and cellular heterogeneity of glioblastoma and laid emphasis that we 
should begin to consider each individual glioblastoma to be an ensemble of distinct 
subclones that reflect a spectrum of dynamic cell states. And this knowledge par-
tially explains this entity’s resistance to treatment, as well as allows new researches 
and strategies to overcome it.
2.4 Immunosuppressive environment of brain tissue
A detailed understanding of the supportive role that the microenvironment 
plays in glioblastoma (GBM) is critical to the design of effective immunotherapeutic 
strategies. Glioma histology shows that >30% of GBM tumors are composed of 
infiltrating microglia [20] with active recruitment of peripheral macrophages [21]. 
The secretion of immunomodulatory cytokines from GBM cells, including interleu-
kins 10 (IL-10), 4 (IL-4), and 6 (IL-6), and, particularly, tumor growth factor-beta 
(TGF-β) in addition to prostaglandin E2 can suppress microglia activation.
Tumor-associated macrophages (TAM) [22] are often considered to be facilita-
tors of tumor growth because of their proangiogenic and immunosuppressive 
properties. Besides it, the glioma tumor cells are between the least immunogenic 
in the spectrum of the human tumors, which confer then to be less responsive to 
immunotherapy [23].
Therefore, a complex system allows tumor cells to grow without immune system 
control, and this knowledge opens new avenues to exploration of immunotherapeu-
tic issues.
3. Glioma classification
The new version of the World Health Organization Classification of Tumors of 
the Central Nervous System (WHO 2016) [24] introduced the concept of an inte-
grated diagnosis, based on a union of both phenotypic (microscopic) and genotypic 
parameters. Major changes are seen in glioma and medulloblastoma groups. Fewer 




In the previous version, WHO 2007, all astrocytic tumors had been grouped 
together, but now in new 2016 classification, all diffuse gliomas whether they are 
astrocytic or oligodendroglial are grouped under one heading, mainly based on 
their growth pattern, behavior, as well as a mutation in IDH.
Regarding the histological classification at the WHO 2016, there were few 
modifications; tumors are still being classified as grade I, II, III, and IV; and just a 
new category “grade unknown” is added for diffuse leptomeningeal glioneuronal 
tumor [25].
3.1 Nomenclature
The nomenclature of the combination of histopathological and molecular fea-
tures must be standardized to simplify its use; CNS tumor diagnoses should consist 
of a histopathological name followed by the genetic features, with the genetic 
features following a comma and as adjectives, as in diffuse astrocytoma, IDH mutant, 
and medulloblastoma, wingless (WNT) activated. If there are more than one genetic 
features, it must be included in the description, for example, oligodendroglioma, IDH 
mutant and 1p/19q co-deleted. When the tumor has no genetic alteration, the term 
“wild type” might be used if an official entity already exists, for example, glioblas-
toma IDH wild type.
For situations which there are no access to molecular tests, or it was not done, 
by whatever reason, the term not otherwise specified (NOS) must be used, for 
example, diffuse astrocytoma, NOS. For instance, the NOS terminology refers to an 
incomplete or unavailable information related to molecular tests.
3.2 Gliomas
Despite having astrocytic or oligodendroglial features, in the WHO 2016, they 
are grouped together as diffuse gliomas, and for pathologic point of view, it is 
useful, so they are grouped together; for prognostic issues and patient management, 
the therapeutic orientation might be driven biologically and genetically.
Astrocytic gliomas include diffuse lesions, which may be grade II, grade III 
(anaplastic), and grade IV (glioblastoma), and main molecular features are IDH 
and alpha-thalassemia/mental retardation syndrome X-linked (ATRX) gene. 
IDH-mutated lesions may have better evolution. Grades II and III are mainly IDH 
mutated, whereas grade IV (glioblastoma) is predominately IDH wild type.
Oligodendroglial tumors have their histological features; although astrocytic 
ones might have its feature as well, and its molecular features are IDH mutated and 
1p/19q co-deleted, these classes of tumors have better prognosis. It may have grade 
II and grade III (anaplastic). When the genetic tests are not available, it will be 
classified as diffuse astrocytoma, NOS; oligodendroglioma, NOS; or glioblastoma, 
NOS.
4. Glioma molecular markers
4.1 IDH1 and IDH2
IDH is the most important diagnostic marker as it can differentiate glioma from 
gliosis. These mutations have affected amino acid 132 of isocitrate dehydrogenase 
1 gene (IDH1) in more than 70% of the WHO grade II and III astrocytomas and 
oligodendrogliomas and in glioblastomas that have developed from these lower-
grade lesions [26].
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Two IDH variants have been used, IDH1 and IDH2, which are enzymes in Krebs 
cycle that catalyzes the conversion of isocitrate to alpha-ketoglutarate. IDH1 muta-
tions are heterozygous, and these are involving an amino acid substitution (glycine 
to arginine) in the active site of the enzyme in codon 132 (R132H). This mutation 
results in the abnormal production of 2-hydroxyglutarate, which causes histone and 
deoxyribonucleic acid (DNA) methylation, hence promoting tumorigenesis [27], 
while IDH2 variants are reported to influence angiogenesis, apoptosis, and glucose 
metabolism [28].
IDH can be demonstrated by IDH1 or IDH2 mutation by immunohistochemistry 
using mutation-specific antibody against R132H-mutant IDH1; if immunostaining 
is negative, then it should be followed by IDH1/IDH2 DNA genotyping. Mutation 
in both IDH1 and IDH2 entities is known as IDH mutant. When both are negative, 
then it is known as IDH wild type. If IDH testing is not available or cannot be fully 
performed or is inconclusive, then it is labeled as IDH NOS.
4.2 1p/19q co-deletion
In 1p/19q co-deletion, there is a complete deletion of both the short arm of 
chromosome 1 (1p) and the long arm of chromosome 19 (19q). 1p/19q co-deletion 
can be demonstrated by fluorescent in situ hybridization (FISH), polymerase chain 
reaction, chromogenic in situ hybridization, or molecular genetic testing. It is 
definitive for the diagnosis of grade II and grade III (anaplastic) oligodendroglio-
mas. It is a strong prognostic factor associated with improved survival and also a 
predictive factor for response to chemotherapy as well as radiotherapy [29, 30].
4.3 O6-methylguanine-DNA methyltransferase methylation (MGMT)
The MGMT gene encodes a DNA repair enzyme that can nullify the effects 
of alkylating chemotherapy such as temozolomide [31]. The alkylating chemo-
therapy damages DNA by adding methyl groups. Therefore, a tumor with a high 
degree of MGMT activity will be resistant to chemotherapies which target DNA at 
this location. If the promoter region of the MGMT gene is unmethylated, the gene 
will be active, whereas if the promoter region of MGMT is hypermethylated, the 
gene will be silenced. However, if the MGMT gene is active, the damage is rapidly 
repaired. Methylation of the MGMT gene promoter is a favorable prognostic and 
predictive factor in glioblastoma patients, but it is not a diagnostic marker for the 
same.
The correlation with other biomarkers is mandatory to have oriented treatment 
in neuro-oncology [32].
4.4 TERT (telomerase reverse transcriptase) promoter mutations
TERT mutations often involve C228T and C250T mutations of the promoter 
region. TERT promoter mutations and long telomere length predict poor survival 
and radiotherapy resistance in gliomas. It occurs mainly in glioblastoma and oligo-
dendroglioma. TERTp and IDH mutations are routinely used clinically to facilitate 
diagnosis by classifying 80% of GBMs into molecular subgroups with distinct 
clinical courses [30, 33].
4.5 Alpha-thalassemia/mental retardation syndrome X-linked (ATRX)
It is a chromatin-remodeling protein important in DNA replication, telomere 
stability, gene transcription, chromosome congression, and cohesion during cell 
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division. ATRX mutation results in lengthening of telomerase which helps in chro-
matin maintenance and remodeling. All cells are ATRX positive. If ATRX mutation 
is present, then there will be a loss of staining in the cells [34].
ATRX mutations are almost always accompanied by other mutations in the 
histone regulation (IDH, H33 K27M, tumor protein p53 [TP53], etc.) [35]. Loss 
of ATRX expression is seen in 45% of anaplastic astrocytoma, 27% of anaplastic 
oligoastrocytoma, and 10% of anaplastic oligodendroglioma and also in pediatric 
and adult high-grade astrocytoma [36].
4.6 Tumor protein p53
p53 is a tumor suppressor gene located on the short arm of chromosome 17. Loss 
of p53 leads to DNA damage, hypoxia, oncogene activation, microtubule disrup-
tion, and oxidative damage which in turn contributes to the CNS tumor patho-
genesis mainly medulloblastoma, glioblastoma, and in 56–58% of IDH-mutant 
astrocytoma [37]. Copy number neutral loss of heterozygosity of chromosome 17p 
(CNLOH 17p) was nearly exclusively associated with IDH1-mutant astrocytoma 
with TP53 mutations. “CNLOH” means that one copy of the chromosome has been 
deleted, whereas the remaining copy has been duplicated. The net result is that the 
cell still has a total of two copies of the gene or chromosomal segment, but instead 
of having two different copies, a single copy has been duplicated. CNLOH 17p was 
found to be a significant prognostic factor, with better survival outcomes for those 
with the CNLOH 17p alteration [38].
5. Low-grade gliomas
Usually, the term “low-grade glioma” refers to the glioma class, which has an 
indolent evolution and an incurable disease, and during their evolution transform 
into a high grade. It has a specific molecular and genetic profile. In the WHO 2016, 
they are represented by diffuse astrocytic glioma grade II, IDH mutant and IDH 
wild type, and diffuse oligodendroglioma, IDH mutant with 1p/19q co-deletion or 
not [39].
Surgery is a key point on its management, getting tissue for biopsy and molecu-
lar analysis, and the timing depends on some variables, such as tumor size, localiza-
tion, age of patient, and symptoms. Patients with small tumors might be followed 
regularly; despite not having randomized studies, early intervention has been 
showing OS advantages, as well the extension of resection and maximum safe resec-
tion rather than partial resection or biopsy [40–42].
Radiation therapy is an important part of the low-grade glioma treatment, and 
the optimal timing is controversial; by the way, for those ones with high risk of 
relapse, the immediate delivery of radiation is of the standard approaches [43].
Regarding the systemic treatment, chemotherapy is part of its treatment in the 
adjuvant and at relapse setting of the low-grade glioma spectrum.
In RTOG 9802, patients were randomly assigned to radiation therapy (RT) alone 
or RT followed by six cycles of procarbazine, lomustine, and vincristine (PCV). The 
primary endpoint was OS, and the secondary endpoint was PFS and grade III toxic-
ity. At the time of the first publication [44] with a median follow-up of 5.9 years in 
surviving patients, there was a trend toward longer survival in the RT plus chemo-
therapy group (5-year overall survival 72 vs. 63%, hazard ratio [HR] 0.72, 95% CI 
0.47–1.10), but with a median follow-up of 11.9 years showed at second publication 
[45], the significance of OS and progression-free survival (PFS) was reached, with 
median overall survival 13.3 vs. 7.8 years for patients treated with RT followed by 
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PCV, HR 0.59, p = 0.03, and the median progression-free survival was also pro-
longed in patients who received PCV (10.4 vs. 4.0 years, p = 0.002).
These results bring level 1 evidence to treat high-risk patients with low-grade 
gliomas with RT and PCV. As PCV is toxic and there are further evidences of 
equivalences with temozolomide [46], despite not being randomized by studies 
comparing it in this population, this drug can be used with the 2B level of evidence. 
At CATNON trial, there was a comparison in patients with anaplastic oligodendro-
gliomas with no co-deletion, between RT and RT followed by temozolomide, with 
OS advantage.
In the subgroup of patients who had had 1p/19q co-deletion, the significance 
of benefit from PCV was greater in patients with oligodendroglioma (n = 101; HR 
0.43, 95% CI 0.23–0.82) and oligoastrocytoma (n = 77; HR 0.56, 95% CI 0.32–1.0) 
than in those with astrocytoma (n = 46; HR 0.73, 95% CI 0.40–1.34).
6. High-grade gliomas
This category is composed by grade III diffuse gliomas (anaplastic astrocytoma, 
anaplastic oligodendroglioma) and grade IV (glioblastoma). Typically, the symp-
tom evolution occurs in few weeks or months. Among them, there are different 
prognoses, so as anaplastic oligodendroglioma has OS of 9 years, anaplastic astrocy-
toma has OS of 3–5 years, and glioblastoma has OS of just 15 months. The prognosis 
will be dependent on age, performance status, localization of the lesion, grade of 
resection [47, 48], and molecular profile for grade III diffuse gliomas (IDH and 
1p/19q co-deletion) and for glioblastoma (IDH status, MGMT, TERT, p53, epider-
mal growth factor receptor variant III (EGFRvIII), and others).
Surgery for high-grade gliomas has the goal of maximum safe resection [49], 
with prognosis improvement, or at least partial resection or stereotactic biopsy to 
define histology, as well as molecular markers to drive treatment. Many strategies 
have been tested to reach maximum safe resection, such as awake surgery, intra-
operative magnetic resonance [50], 5-aminolevulinic acid (5-ALA) guide surgery 
[48], and other techniques that require expertise and facilities to deal with these 
demands.
Further adjuvant treatment, considering gold standard, using radiation therapy 
and systemic treatment is required. To revisit this issue, it might be considered that 
previous trials took data from a mix of histologic and molecular subtypes, not tak-
ing in account the updated WHO 2016.
6.1 Grade III diffuse gliomas
6.1.1 Anaplastic oligodendroglioma
In this subtype, the knowledge of the role of 1p/19q co-deletion as better prog-
nostic marker as far has been demonstrated [51]. According to the WHO 2016, this 
tumor must have IDH mutation and 1p/19q co-deletion.
One of the evidences to treat this class of patient with combination of radiation 
therapy and chemotherapy was demonstrated in EORTC brain tumor group study 
26951 [29], where 368 adult patients with newly diagnosed anaplastic oligoden-
droglial tumors were randomly assigned to either RT or the same RT followed by 
six cycles of adjuvant PCV, and with a median follow-up of 140 months, OS in the 
RT/PCV arm was significantly longer (42.3 vs. 30.6 months in the RT arm, hazard 
ratio [HR], 0.75; 95% CI, 0.60–0.95). In an exploratory analysis of 80 patients 
with a 1p/19q co-deletion, OS was increased, with a trend toward more benefits 
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from adjuvant PCV (OS not reached in the RT/PCV group vs. 112 months in the RT 
group; HR, 0.56; 95% CI, 0.31–1.03). IDH mutational status was also of prognostic 
significance.
At RTOG 9402 in an updated publication [52], 291 patients with anaplastic 
oligodendrogliomas and pure (AO) and mixed (anaplastic oligoastrocytoma (AOA) 
were randomized to four cycles of PCV followed by radiation therapy (RT). For the 
entire cohort, there was no difference in median survival by treatment (4.6 years for 
PCV plus RT vs. 4.7 years for RT), but for 1p/19q co-deleted patients as in EORTC 
26951, there was survival benefit, although this analysis was not preplanned.
6.1.2 Anaplastic astrocytoma
In the WHO 2016, anaplastic astrocytoma molecular feature is IDH1/IDH2 
mutated and IDH1/IDH2 wild type, with no 1p/19q co-deletion. Anaplastic 
 astrocytoma IDH1/IDH2 wild type has worse prognosis than the IDH1/IDH-2 
mutated [25].
At CATNON trial (EORTC study 26053-22054) [8], 745 patients (99%) of the 
planned 748 patients, with anaplastic astrocytoma with no 1p/19q co-deletion, had 
been enrolled in a four-arm study comparing RT alone, RT with concurrent daily 
temozolomide, RT followed by 12 cycles of adjuvant temozolomide, and RT with 
both concurrent and 12 cycles of adjuvant temozolomide. At the interim analysis 
of RT × RT followed by 12 cycles of adjuvant temozolomide, the temozolomide 
addition had a significant improvement in both progression-free survival (HR 0.62, 
95% CI 0.50–0.76) and overall survival (median 44.1 months vs. not yet reached; 
HR 0.65, 95% CI 0.45–0.93).
So, based upon CATNON trial and other observations [53, 54], patients with 
anaplastic astrocytoma must be treated with adjuvant RT and chemotherapy, and 
if IDH is wild type, it must be treated as glioblastoma. To IDH-mutated lesions, 
until final analysis of CATNON trial, there is no evidence-based data supporting 
concomitant adjuvant treatment for this subgroup.
6.2 Grade IV gliomas: glioblastoma
Glioblastoma has been a daily challenge for those who attend these patients, as 
well for those who are involved in research area. Glioblastoma is the most common 
glioma and usually has dismal evolution in few months or years, so it has OS of 
just 15 months. At the Stupp trial [2], in the current standard of care of postopera-
tive therapy for glioblastoma, 573 newly diagnosed patients with histologically 
confirmed glioblastoma were randomly assigned to receive radiotherapy alone 
or radiotherapy plus continuous daily temozolomide, followed by six cycles of 
adjuvant temozolomide. At a median follow-up of 28 months, the median survival 
was 14.6 months with radiotherapy plus temozolomide and 12.1 months with 
radiotherapy alone. The unadjusted hazard ratio for death in the radiotherapy plus 
temozolomide group was 0.63 (95% confidence interval, 0.52–0.75; P < 0.001 by 
the log-rank test).
At this trial and others [55, 56], MGMT-methylated patients are doing better, 
and this biomarker became a strong predictor of temozolomide response.
Low-intensity alternating electric field therapy (TTFields) is a novel treatment 
to glioblastoma, in which locoregionally delivered antimitotic treatment interferes 
with cell division and organelle assembly. This stimulus is delivered continuously 
by transducers applied to a shaved scalp. In an open-label randomized trial of 
695 adults with newly diagnosed glioblastoma, median survival was improved in 
patients assigned to wear the device during the adjuvant temozolomide phase of 
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standard chemoradiation compared with those assigned to standard chemora-
diation alone (21 vs. 16 months) [57, 58]. The requirement to carry a device and 
maintain a shaved scalp for the duration of treatment presents a potential burden 
that is not acceptable to all patients [59].
On a phase II study [60], 39 glioblastoma patients are offered with radiotherapy 
of tumor site only and CCNU/TMZ (carmustine/temozolomide) chemotherapy 
for up to six courses. It results in a longer survival when compared to historical 
controls, mainly in MGMT-methylated patients; in the whole cohort, the median 
overall survival (mOS) was 23.1 months, and comparing MGMT methylated or not, 
the mOS was significantly longer with 34.3 vs. 12.5 months. The WHO grade IV 
hematologic toxicity was frequent.
CeTeG/NOA-09 trial was designed to prove that MGMT-methylated glioblas-
toma patients might have better survival using CCNU/TMZ. In this trial, there was 
randomization between MGMT-methylated glioblastoma patients to treat with a 
standard Stupp protocol vs. six cycles of CCNU/TMZ, its results were presented 
at plenary section of 22nd SNO (Society of Neuro-oncology meeting) [61], and it 
results in mOS for TMZ of 30.4 and 46.9 months for CCNU/TMZ. These are chal-
lenging results, waiting for publication for further details.
7. New strategies to treat gliomas
In the last 30 years, there have been huge investments in glioma research for bet-
ter outcomes; despite being fruitful, it is far from being solved. There are studies in 
anti-angiogenic drugs, inhibition of integrins, inhibition of growth factor receptors 
and intracellular signaling pathways, and immunotherapy, and despite failing to 
improve OS, immunotherapy has demonstrated hopeful results.
Immunotherapy has been extensively studied, with better understanding 
of relationship between tumors and immune system [62], and it is totally clear 
that immune system plays a key role in the tumor evolution as well as its control. 
Currently, immunotherapy has been standard in a growing spectrum of tumors 
[63, 64].
Immunotherapy challenges in glioblastoma, owing to low mutational load 
(TML) and therefore potential immunogenicity, and tight immune regulation 
within the CNS result in limited T-cell effector responses, which means that immu-
nosuppressive microenvironment and blockade of some cells to CNS have been 
limited for better use of this strategy in glioma field.
7.1 Vaccines
As an active immunotherapy (vaccine), rindopepimut (Rintega) consists of an 
EGFRvIII peptide conjugated to keyhole limpet hemocyanin, which is expressed 
in 30% of cells from glioblastoma patients and was previously tested in a phase II 
trial (ACT III) [65], and it had been the first immunotherapeutic to demonstrate 
increased survival. The hypothesis had been tested in a phase III trial, ACT IV [66], 
in which patients with newly diagnosed GBM with EGFRvIII expressed treated with 
standard chemoradiation with or without rindopepimut. Its publication showed 
that there was no difference at primary endpoint, with OS of 20.4 vs. 21.1 months. 
There are some evidences of association between bevacizumab and rindopepimut 
having synergistic effect [67], but this hypothesis must be proven.
Another provocative strategy has just been published [68] in a phase III trial 
which evaluates the addition of an autologous tumor lysate-pulsed dendritic cell 
vaccine (DCVax®-L) to standard therapy for newly diagnosed glioblastoma. 
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The final results are not yet available, because they are still unblinded, until the suf-
ficient events have occurred to elucidate the final curves. Despite being an interim 
analysis, it has been shown 23.4 months of medium OS (mOS), as the intention-to-
treat (ITT) population is similar, and it was allowed to crossover. So, we have to wait 
for the final data.
7.2 Checkpoint inhibitors
Another promising area is immunotherapy with checkpoint inhibitors, although 
a recent trial failed to demonstrate survival benefit. The CheckMate 143 was the 
first randomized phase III clinical trial in GBM with a PD-1 checkpoint inhibitor. 
In nivolumab alone vs. bevacizumab alone in recurrent GBM, 369 patients were 
randomized to the nivolumab (n = 184) or bevacizumab (n = 185), resulting in 
a median OS of 9.8 months with nivolumab and 10 months with bevacizumab, 
and the 12-month OS rate was 42% in both arms. Despite having failed to dem-
onstrate advantage, in a specific scenario, in patients with biallelic mismatch 
repair deficiency (bMMRD), it can benefit from checkpoint inhibitor treatment 
[69]. This might be explained by a high mutational burden in bMMRD. In other 
considerations, CheckMate 143 failure involves an inability of nivolumab to reach 
tumor-infiltrating lymphocytes (TILs) already sequestered in the recurrent tumor 
microenvironment; it may be expected to function better in patients with newly 
diagnosed GBM, where newly activated circulating T cells would be available for 
interaction with nivolumab prior to their migration to tumor sites. So, further 
investigation is required to set PD-1 checkpoint in glioma treatment [70, 71].
7.3 CAR T cells
Tumor immunotherapy with T lymphocytes, which can recognize and destroy 
malignant cells, has been limited by the ability to isolate and expand T cells 
restricted to tumor-associated antigens. Chimeric antigen receptors (CARs) 
composed of antibody-binding domains connected to domains that activate T cells 
could overcome tolerance by allowing T cells to respond to cell surface antigens; 
however, to date, lymphocytes engineered to express CARs have demonstrated 
minimal in vivo expansion and antitumor effects in clinical trials [72]. The very 
begging publications related to CAR T-cell therapy were related to a relapsed and 
refractory acute lymphoblastic leukemia, which made this technology known.
At glioma setting, CAR T-cell therapy has been tested, in recurrent GBM utiliz-
ing CAR T-cell GBM-associated antigen IL13Ra2 that utilizes CD62L-enriched 
central memory T cells (Tcm) engineered by lentiviral transduction to express 
[73]. Second-generation 4-1BB-containing CAR (IL13BBZ) signaling domain was 
utilized by both intratumoral and intraventricular deliveries, with multiple doses 
via reservoir. Safely and well tolerated, some dramatic responses were observed, 
both in brain and meninx lesions.
Further efforts have been made to improve results of this therapy [74–76].
7.4 Cancer-targeting oncolytic viruses
Cancer virotherapy mediated by oncolytic viruses (OV) has emerged as a novel 
and effective strategy in cancer therapeutics [77]. Desjardins [78] in a dose-finding 
and toxicity phase I study evaluated an intratumoral delivery of the recombinant 
nonpathogenic poliovirus-rhinovirus chimera (PVSRIPO). PVSRIPO recognizes 
the poliovirus receptor CD155, which is widely expressed in neoplastic cells of solid 
tumors and in major components of the tumor microenvironment. Overall survival 
11
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 




1 Curitiba’s Neurologic Institute (INC), Parana’s Oncology Institute (IOP), Curitiba, 
Brazil
2 Brazilian Society of Clinical Oncology, American Society of Clinical Oncology, 
Brazil
*Address all correspondence to: jfccamargo@gmail.com
among the patients who received PVSRIPO reached a plateau of 21% (95% confi-
dence interval, 11–33) at 24 months that was sustained at 36 months. For glioma 
grade IV with standard treatment, there is no plateau. A phase II study in this 
setting is ongoing NCT02986178.
8. Conclusions
Glioma treatment is still a challenge, and its quality is related to integrated team, 
in which the systemic treatment must be based on awareness of drug limitation 
usage and keeping in mind strategies to overcome these issues.
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